Jeffrey M. Yordon, CEO of Sagent, said: “Since our inception in 2006, Sagent has successfully executed its strategy by filing more than 70 aNDAs to date, with more than 20 products expected in the market by year end. We appreciate our investors’ continued confidence and commitment to Sagent.”
Sagent is engaged in the development, manufacturing and marketing of pharmaceutical products, with focus on injectable products. The company’s product portfolio constitutes more than 200 products in various stages of development.